{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=San+Antonio&page=20&state=Texas",
    "query": {
      "state": "Texas",
      "city": "San Antonio",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 3154,
    "total_pages": 316,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=San+Antonio&page=21&state=Texas&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=San+Antonio&page=19&state=Texas&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T16:19:56.726Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02513797",
      "title": "aMAZE Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "LARIAT + PVI",
          "type": "DEVICE"
        },
        {
          "name": "Pulmonary Vein Isolation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "AtriCure, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 600,
      "start_date": "2015-09",
      "completion_date": "2022-03",
      "has_results": false,
      "last_update_posted_date": "2021-09-05",
      "last_synced_at": "2026-11-04T16:19:56.726Z",
      "location_count": 53,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 44 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02513797"
    },
    {
      "nct_id": "NCT03562637",
      "title": "Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "adagloxad simolenin combined with OBI-821",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Globo H IHC Assay",
          "type": "DEVICE"
        },
        {
          "name": "Standard of care treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "OBI Pharma, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 575,
      "start_date": "2018-12-05",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-05-09",
      "last_synced_at": "2026-11-04T16:19:56.726Z",
      "location_count": 12,
      "location_summary": "La Jolla, California • San Diego, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03562637"
    },
    {
      "nct_id": "NCT06291415",
      "title": "The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Immune Thrombocytopenia",
        "Blood Platelet Disorder",
        "Hematologic Diseases",
        "Purpura, Thrombocytopenic",
        "Purpura",
        "Blood Coagulation Disorder",
        "Thrombotic Microangiopathies",
        "Hemorrhagic Disorders",
        "Autoimmune Diseases",
        "Immune System Diseases",
        "Hemorrhage",
        "Pathologic Processes",
        "Skin Manifestations",
        "Thrombocytopenia",
        "Purpura, Thrombocytopenic, Idiopathic",
        "Primary Immune Thrombocytopenia",
        "ITP - Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "HMPL-523",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-04-02",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-11-04T16:19:56.726Z",
      "location_count": 10,
      "location_summary": "Irvine, California • Georgetown, Delaware • Bethesda, Maryland + 7 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Georgetown",
          "state": "Delaware"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Farmington",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06291415"
    },
    {
      "nct_id": "NCT04036435",
      "title": "Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "BMS-986165",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1466,
      "start_date": "2019-08-12",
      "completion_date": "2026-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-11-04T16:19:56.726Z",
      "location_count": 101,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 77 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04036435"
    },
    {
      "nct_id": "NCT03926117",
      "title": "Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Diseases",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Ziltivekimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 264,
      "start_date": "2019-06-03",
      "completion_date": "2020-06-26",
      "has_results": true,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-11-04T16:19:56.726Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lynwood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03926117"
    },
    {
      "nct_id": "NCT00783718",
      "title": "Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "vedolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 895,
      "start_date": "2009-01",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2014-07-18",
      "last_synced_at": "2026-11-04T16:19:56.726Z",
      "location_count": 102,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Montebello, California + 82 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Montebello",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00783718"
    },
    {
      "nct_id": "NCT01243424",
      "title": "CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "linagliptin",
          "type": "DRUG"
        },
        {
          "name": "glimepiride",
          "type": "DRUG"
        },
        {
          "name": "linagliptin placebo",
          "type": "DRUG"
        },
        {
          "name": "glimepiride placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 6103,
      "start_date": "2010-11-11",
      "completion_date": "2018-08-21",
      "has_results": true,
      "last_update_posted_date": "2020-01-07",
      "last_synced_at": "2026-11-04T16:19:56.726Z",
      "location_count": 177,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 139 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01243424"
    },
    {
      "nct_id": "NCT03809624",
      "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Non-small Cell Lung Cancer",
        "Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Gastric Adenocarcinoma",
        "Renal Cell Carcinoma",
        "Esophageal Adenocarcinoma",
        "Nasopharyngeal Carcinoma",
        "Oropharyngeal Carcinoma"
      ],
      "interventions": [
        {
          "name": "INBRX-105 - PDL1x41BB antibody",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inhibrx Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2019-01-30",
      "completion_date": "2024-10-03",
      "has_results": false,
      "last_update_posted_date": "2024-10-23",
      "last_synced_at": "2026-11-04T16:19:56.726Z",
      "location_count": 23,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03809624"
    },
    {
      "nct_id": "NCT02541604",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 87,
      "start_date": "2015-11-30",
      "completion_date": "2019-06-06",
      "has_results": true,
      "last_update_posted_date": "2020-02-25",
      "last_synced_at": "2026-11-04T16:19:56.726Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Palo Alto, California • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02541604"
    },
    {
      "nct_id": "NCT00050778",
      "title": "A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Interferon beta-1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alemtuzumab 12 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alemtuzumab 24 mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 334,
      "start_date": "2002-12",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-11-04T16:19:56.726Z",
      "location_count": 31,
      "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 27 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00050778"
    }
  ]
}